Obsessive compulsive disorder
Drug research and approvals for obsessive compulsive disorder: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 124 studies of obsessive compulsive disorder are recruiting on ClinicalTrials.gov, Health Canada has authorized 10 drug trials for it since 2013, and FDA has 0 approved and 1 open orphan designations naming it.
- Recruiting worldwide: 124
- Trials authorized in Canada: 10
- FDA orphan approvals: 0
- EU medicines: 0
- SONATA Dose Duration LIFU for OCDNCT07887633 · Phase 2 · University of Pennsylvania · starts Sep 15, 2026
- Focused Ultrasound for Behavioral HealthNCT07851038 · Not applicable · Attune Neurosciences Inc · starts Oct 19, 2026
- Clinical and Biological Correlates of Obsessive-Compulsive Disorder and Online Mindfulness-Based Cognitive TherapyNCT07834567 · Not applicable · IRCCS Centro San Giovanni di Dio Fatebenefratelli · starts Aug 26, 2026
- Efficacy and Mechanism of Transcranial Temporal Interference Stimulation (tTIS) for Patients With Obsessive-Compulsive…NCT07805200 · Not applicable · Beijing HuiLongGuan Hospital · starts Oct 16, 2026
- Anxiety Skills StudyNCT07774481 · Not applicable · Ohio State University · starts Oct 20, 2025
- Treatment Resistance in Psychiatric Disorders: the Search for Biological Markers Predictive of Response to TreatmentNCT07741981 · Not applicable · Centre Hospitalier St Anne · starts Aug 20, 2026
- SONATA LIFU for OCDNCT07728994 · Phase 2 · University of Pennsylvania · starts Jul 1, 2026
- Integrating Exposure and Response Prevention and Habit Reversal Techniques to Treat a Tourettic Subtype of…NCT07725926 · Not applicable · University College London Hospitals · starts Jul 8, 2026
- Safety and Feasibility of FUS Next Generation Dome Helmet (NGDH) to Perform Neuromodulation in Patients With Treatment…NCT07704632 · Not applicable · Sunnybrook Health Sciences Centre · starts Sep 23, 2025
Approved 5
- SertralineSerotonin transporter inhibitor
- FluvoxamineSerotonin transporter inhibitor
- ClomipramineSerotonin transporter inhibitor
- FluoxetineSerotonin transporter inhibitor
- ParoxetineSerotonin transporter inhibitor
Phase 3 8
- CycloserineD-alanylalanine synthetase inhibitor
- MemantineGlutamate [NMDA] receptor negative allosteric modulator
- Troriluzole
- EscitalopramSerotonin transporter inhibitor
- VenlafaxineSerotonin transporter inhibitor
- CitalopramSerotonin transporter inhibitor
- QuetiapineSerotonin 2a (5-HT2a) receptor antagonist
- TopiramateCarbonic anhydrase II inhibitor
Phase 2 12 of 28
- KetamineGlutamate [NMDA] receptor negative allosteric modulator
- MidazolamGABA-A receptor; anion channel positive allosteric modulator
- AcetylcysteineGlutathione precursor
- CelecoxibCyclooxygenase-2 inhibitor
- TolcaponeCatechol O-methyltransferase inhibitor
- NaltrexoneOpioid receptors; mu/kappa/delta antagonist
- MinocyclineBacterial 70S ribosome inhibitor
- PramipexoleD2-like dopamine receptor agonist
- AripiprazoleDopamine D2 receptor partial agonist
- FlumazenilGABA-A receptor; anion channel allosteric antagonist
- MethamphetamineMonoamine transporter inhibitor
- OxytocinOxytocin receptor agonist
Phase 1 or earlier 6
- PsilocybinSerotonin 2a (5-HT2a) receptor agonist
- NabiloneCannabinoid CB1 receptor agonist
- LorazepamGABA-A receptor; anion channel positive allosteric modulator
- AmisulprideSerotonin (5-HT) receptor antagonist
- Niacin
- Cannabinol
How its trials ended
552 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 103 whose ending is known, 49% met their primary endpoint, 6% missed it and 46% stopped early.
- Completed, result not reported23342%
- Ongoing15929%
- Status unknown5710%
- Met its primary endpoint509%
- Stopped: other or unclear295%
- Stopped: enrollment or feasibility102%
- Missed its primary endpoint61%
- Stopped: sponsor or business decision31%
- Stopped: funding31%
- Stopped: lack of efficacy2<1%
| Feb 27, 2026 | Imaging presynaptic density in obsessive compulsive disorder with/without comorbid major depressive disorder[18F]SDM-8 inj / [18F]BCPP-EF | Centre for Addiction and Mental Health | Ongoing |
| Oct 24, 2023 | Evaluating the feasibility, clinical effects, and safety of psilocybin-assisted psychotherapy for treatment-resistant obsessive-compulsive disorder: an…Psilocybin (PEX010) | Centre for Addiction and Mental Health | Ongoing |
| Jan 13, 2023 | A clinical trial to evaluate the safety and efficacy of fecal microbiota transplantation in a population with obsessive-compulsive disorderIntestinal microbes recovered from filteration, suspension and ultrafiltration… | Governors of The University of Calgary | Ongoing |
| Aug 3, 2022 | Psilocybin assisted therapy for anxiety and mood disorders: a transdiagnostic open label clinical trial for improving well-being (pam-well)Psilocybin | Brain and Cognition Discovery Foundation | Closed |
| Jul 8, 2021 | Assessment of safety and feasibility of exablate neuro system to perform echo-focusing echo imaging in patients with treatment-resistant neurologic and…Definity (perflutren) | Insightec | Pending |
| Jun 2, 2021 | A randomized sham and placebo-controlled trial of adjunctive d-cycloserine in repetitive transcranial magnetic stimulation for obsessive compulsive disorderCycloserine | Governors of The University of Calgary | Ongoing |
| Feb 10, 2021 | A randomized, double-blind, placebo-controlled trial of adjunctive troriluzole in obsessive compulsive disorder.Troriluzole (BHV-4157) | Biohaven Therapeutics | Ongoing |
| Feb 10, 2021 | A multicenter, long-term open-label safety study of adjunctive troriluzole in subjects with obsessive compulsive disorderTroriluzole (BHV-4157) | Biohaven Therapeutics | Ongoing |
| Jan 12, 2021 | Celecoxib versus placebo as an adjunct to treatment-as-usual in children and youth with obsessive compulsive disorder: a single-site randomized quadruple-blind…Celecoxib | The University of British Columbia & BC Children's Hospital Research Institute | Ongoing |
| Jun 26, 2013 | A phase II, multi-center, randomized, double-blind, parallel-group, placebo-controlled study to evaluate efficacy and safety of RO4917838 in combination with…Bitopertin (RO4917838) | Roche | Closed |
| Date | Drug | Sponsor | Status |
|---|---|---|---|
| Oct 12, 2011 | SarcosineTreatment of obsessive compulsive disorder in pediatric patients (0 to 16 years of age) | Guochuan Emil Tsai, MD, PhD | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA